Endo signs $210 million Fortigel deal with ProStrakan
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals is to pay ProStrakan $210 million for the US licensing and distribution rights to the UK firm's yet to be approved 2% testosterone gel Fortigel.